Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Nab-Paclitaxel Plus Sintilimab as Second-Line Treatment for Patients With Advanced BTC: A Phase 2 Study
Read More
Cholangiocarcinoma
Phase 2 Trial of Nivolumab With or Without Ipilimumab Plus SBRT in Patients With Pretreated Advanced BTC
Read More
Cholangiocarcinoma
The Cost-Effectiveness of GemCis With or Without Durvalumab in Patients With Advanced CCA
Read More
Cholangiocarcinoma
NUC-1031 Plus Cisplatin Versus GemCis for First-line Treatment of Advanced BTC, NuTide: 121
Read More
Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Mohammed A. Jaloudi, MD
Read More
Original Research
,
Oncology Pharmacy Programs/Protocols
,
Tyrosine Kinase Inhibitor
,
Leukemia
,
Cost of Care
Clinical Pharmacist–Initiated TKI Discontinuation in Patients with CML
Jared M. Freml, PharmD; Yuliya M. Byakina, PharmD, BCOP; Lisa A. Thompson, PharmD, BCOP; Ekim Ekinci, PharmD, MS, BCOP; Jasen K. Knudsen, PharmD, BCPS, BCOP; Chamath R. De Silva, MD; Soames F. Boyle, MD; Thomas Delate, PhD, MS
Read More
Original Research
,
COVID-19
,
Infections
Real-World Efficacy and Safety of Tixagevimab Plus Cilgavimab in Patients with Cancer
Anhthy Tong, PharmD; Karam Ashouri, MD; Yijun Cai; Ann Mohrbacher, MD; Eduardo Fernandez Hernandez, MD; Samantha Shi, PharmD, BCOP; George Yaghmour, MD; Amir Ali, PharmD, BCOP
Read More
ESMO Early Breast Cancer
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Read More
FDA Updates
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Read More
ESMO Early Breast Cancer
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
23
24
25
26
27
28
29
Page 26 of 196
Results 251 - 260 of 1953
